camostat has been researched along with Pancreatic Diseases in 4 studies
camostat : A benzoate ester resulting from the formal condensation of the carboxy group of 4-guanidinobenzoic acid with the hydroxy group of 2-(dimethylamino)-2-oxoethyl (4-hydroxyphenyl)acetate. It is a potent inhibitor of the human transmembrane protease serine 2 (TMPRSS2) and its mesylate salt is currently under investigation for its effectiveness in COVID-19 patients.
Pancreatic Diseases: Pathological processes of the PANCREAS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of the present study was to examine the potential efficacy of camostat mesilate, a protease inhibitor, against dyspepsia associated with non-alcoholic mild pancreatic disease." | 9.14 | Efficacy of camostat mesilate against dyspepsia associated with non-alcoholic mild pancreatic disease. ( Inami, K; Kubokawa, Y; Matsumura, Y; Sai, JK; Suyama, M; Watanabe, S, 2010) |
| "Camostat has a beneficial effect on pancreatic fibrosis induced by the administration of a SOD inhibitor, which inhibits the proliferation and activation of PSC." | 7.73 | Camostat, an oral trypsin inhibitor, reduces pancreatic fibrosis induced by repeated administration of a superoxide dismutase inhibitor in rats. ( Emori, Y; Ichimura, M; Koide, N; Matsumura, N; Mizushima, T; Ochi, K; Shinji, T; Shirahige, A; Tanimoto, M; Tanioka, H, 2005) |
| "The aim of the present study was to examine the potential efficacy of camostat mesilate, a protease inhibitor, against dyspepsia associated with non-alcoholic mild pancreatic disease." | 5.14 | Efficacy of camostat mesilate against dyspepsia associated with non-alcoholic mild pancreatic disease. ( Inami, K; Kubokawa, Y; Matsumura, Y; Sai, JK; Suyama, M; Watanabe, S, 2010) |
| "Camostat has a beneficial effect on pancreatic fibrosis induced by the administration of a SOD inhibitor, which inhibits the proliferation and activation of PSC." | 3.73 | Camostat, an oral trypsin inhibitor, reduces pancreatic fibrosis induced by repeated administration of a superoxide dismutase inhibitor in rats. ( Emori, Y; Ichimura, M; Koide, N; Matsumura, N; Mizushima, T; Ochi, K; Shinji, T; Shirahige, A; Tanimoto, M; Tanioka, H, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (25.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sai, JK | 1 |
| Suyama, M | 1 |
| Kubokawa, Y | 1 |
| Matsumura, Y | 1 |
| Inami, K | 1 |
| Watanabe, S | 1 |
| Emori, Y | 1 |
| Mizushima, T | 1 |
| Matsumura, N | 1 |
| Ochi, K | 1 |
| Tanioka, H | 1 |
| Shirahige, A | 1 |
| Ichimura, M | 1 |
| Shinji, T | 1 |
| Koide, N | 1 |
| Tanimoto, M | 1 |
| Watanapa, P | 1 |
| Williamson, RC | 1 |
| Oishi, T | 1 |
| Nakagawa, M | 1 |
| Bamba, T | 1 |
| Hosoda, S | 1 |
1 review available for camostat and Pancreatic Diseases
| Article | Year |
|---|---|
Experimental pancreatic hyperplasia and neoplasia: effects of dietary and surgical manipulation.
Topics: Animals; Cricetinae; Diet; Disease Models, Animal; Energy Intake; Esters; Flour; Gabexate; Glycine m | 1993 |
1 trial available for camostat and Pancreatic Diseases
| Article | Year |
|---|---|
Efficacy of camostat mesilate against dyspepsia associated with non-alcoholic mild pancreatic disease.
Topics: Abdominal Pain; Adult; Aged; Dyspepsia; Endosonography; Esters; Female; Gabexate; Guanidines; Humans | 2010 |
2 other studies available for camostat and Pancreatic Diseases
| Article | Year |
|---|---|
Camostat, an oral trypsin inhibitor, reduces pancreatic fibrosis induced by repeated administration of a superoxide dismutase inhibitor in rats.
Topics: Administration, Oral; Animals; Disease Models, Animal; Ditiocarb; Drug Administration Schedule; Este | 2005 |
[Study on the trophic effect of camostate mesilate on ethionine-induced pancreatic injury rat].
Topics: Administration, Oral; Amylases; Animals; Cholecystokinin; Esters; Ethionine; Gabexate; Guanidines; I | 1989 |